Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy

BACKGROUND: Our previous study showed that SLC22A18 downregulation and promoter methylation were associated with the development and progression of glioma and the elevated expression of SLC22A18 was found to increase the sensitivity of glioma U251 cells to the anticancer drug 1,3-bis(2-chloroethyl)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Sheng-Hua, Ma, Yan-Bin, Feng, Dong-Fu, Li, Zhi-Qiang, Jiang, Pu-Cha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610152/
https://www.ncbi.nlm.nih.gov/pubmed/23514245
http://dx.doi.org/10.1186/1479-5876-11-69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610152/
https://www.ncbi.nlm.nih.gov/pubmed/23514245
http://dx.doi.org/10.1186/1479-5876-11-69

Ejemplares similares